| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 Sep 2026 | 25 Sep 2026 |
| Allotment of 1770710 fully paid-up equity shares having a face value of INR 5 each at an issue price of INR 42 each, including a premium of INR 37 each, aggregating to INR 7,43,69,820 only upon conversion of unsecured loan, on a preferential basis, to Brahma Gurbani and Meera Gurbani, pursuant to the special resolution passed by the members of the Company on 10 December 2025 and in accordance with the In-Principle Approval granted by BSE Limited vide letter ref: LOD/PREF/KS/FIP/726/2026-27 dated 28 August 2026. | ||
| Board Meeting | 5 Aug 2026 | 31 Jul 2026 |
| Sampre Nutritions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 inter alia to consider and approve 1. Unaudited standalone and consolidated financial results of the Company for the first quarter ended 30 June 2026 for the financial year 2026-27. 2. Fix the date time and venue for the Thirty-Fifth (35th) Annual General Meeting (AGM) of the Company and to approve the Notice of AGM and other matters connected therewith. 3. Proposal to increase the remuneration for Vishal Gurbani (DIN: 07738685) Whole-Time Director of the Company from INR 1800000 (Indian Rupees Eighteen Lakhs) only per annum to INR 6000000 (Indian Rupees Sixty Lakhs) only per annum with effect from 01 April 2026 subject to the approval of the members at the ensuing AGM of the Company. (i) In compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, the unaudited standalone and consolidated financial results along with the limited review report, is attached for the first quarter ended 30 June 2026 for the financial year 2026-27; (ii) Approval of the 35th AGM of the Company to be held on VC/OAVM Mode on Friday, 04 September 2026, at 11:00 A.M. (IST); and (iii) Proposal to revise the remuneration to Vishal Ratan Gurbani, Whole-time Director of the Company from INR 18 Lakhs per annum to INR 60 Lakhs per annum with effect from 01 April 2026, subject to the approval of the members of the company in the ensuing AGM. (As per BSE Announcement dated on 05.08.2026) | ||
| Board Meeting | 29 May 2026 | 27 May 2026 |
| Audited Results. Sampre Nutritions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited standalone and consolidated financial statements for the quarter and year ended 31 March 2026. In compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, the audited standalone and consolidated financial results along with the independent auditors report, and declaration under Regulation 33(3)(d) is attached for the quarter and year ended 31 March 2026. (As Per BSE Announcement Dated on 29.05.2026) | ||
| Board Meeting | 13 Feb 2026 | 11 Feb 2026 |
| Quarterly Results Sampre Nutritions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the third quarter and nine-month period ended 31 December 2025, and, to appoint a director as a non-executive non-independent additional director. Board meeting outcome for standalone and consolidated unaudited financial results for the third quarter and nine-month period ended 31 December 2025; with appointment of a non-executive non-independent additional director. (As per BSE announcement dated on : 13.02.2026) | ||
| Board Meeting | 5 Nov 2025 | 31 Oct 2025 |
| Sampre Nutritions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and approve unaudited financial standalone and consolidated results for the second quarter and half year ended 30 September 2025; to issue equity shares by way of sweat equity; and conversion of loan into equity shares Purpose of the meeting has been revised (As Per BSE Announcement Dated on 04.11.2025) Board Meeting outcome for standalone and consolidated unaudited financial results for the second quarter and half-year ended 30 September 2025; with issuance and allotment of 1770710 equity shares having face value of INR 5 each at an issue price of INR 42 per equity share (including a premium of INR 37 per equity share) aggregating to INR 7,43,69,820 only on preferential basis to promoters for conversion of their existing unsecured loan in the Company. (As Per BSE Announcement Dated on 05.11.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
